Abstract
BACKGROUND: While standard therapeutic regimens for Kawasaki disease (KD) in children have exhibited some efficacy, they remain far from ideal. Thus, the pursuit of alternative or improved treatment modalities remis clinically critical. OBJECTIVE: This study primarily aimed to assess the effect of dipyridamole (DIP) plus human intravenous immunoglobulin (IVIG) and aspirin (ASP) as to efficacy, antiplatelet aggregation factors, and inflammatory markers in children with KD. METHODS: A total of 95 pediatric KD patients were selected from February 2021 to July 2024, with 44 cases in the control group treated with IVIG + ASP and 51 cases in the research group given DIP in addition to IVIG + ASP. The efficacy, symptom resolution time (defervescence, limb swelling, mucosal congestion, and cervical lymphadenopathy), coronary artery injury, coagulation function (thrombin time [TT], prothrombin time [PT], and activated partial thromboplastin time [APTT]), antiplatelet aggregation factors (erythrocyte sedimentation rate [ESR], white blood cell count [WBC], and platelet count [PLT]), and inflammatory factors (C-reactive protein [CRP], and tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6]) levels were compared between the two groups. RESULTS: The research group exhibited a higher overall treatment efficacy rate, shorter symptom resolution times, and a significantly lower incidence of coronary artery injury compared to the control group. No significant differences were observed between the two groups or before and after treatment within the same group in coagulation function indices. Markedly reduced levels of anti-platelet aggregation factors and inflammatory markers were observed in the research group versus those in the control group. CONCLUSION: DIP in combination with IVIG and ASP significantly enhances treatment efficacy and improves levels of antiplatelet aggregation factors and inflammatory markers in children with KD.